Shang Hai Zheng Quan Bao·2025-12-02 18:32Group 1 - The company held its second extraordinary general meeting of shareholders in 2025, with no resolutions being rejected [2][3] - The meeting was conducted in compliance with the Company Law and the company's articles of association, with a total of 2,639,554,073 shares eligible for voting [2][3] - The meeting was attended by 8 out of 11 directors, including the chairman and CEO, while 3 directors were absent due to other commitments [3] Group 2 - The company announced that its subsidiary, Suzhou Er Ye Pharmaceutical Co., Ltd., received acceptance for its drug registration application for Heparin Sodium Injection from the National Medical Products Administration [8] - The drug is intended for various medical uses, including the prevention and treatment of venous thromboembolism and anticoagulation during surgeries [9][10] - As of October 2025, the cumulative R&D investment for this drug was approximately RMB 8.61 million, with projected sales in China for 2024 estimated at RMB 1.386 billion [10] Group 3 - The company’s subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., received acceptance for its drug registration application for HLX14, a biosimilar of Denosumab [13] - HLX14 has been approved in the US and EU, with a cumulative R&D investment of approximately RMB 320 million as of the announcement date [15] - Global sales for Denosumab products are projected to be around USD 7.463 billion in 2024 [16] Group 4 - The company is involved in a private equity investment fund, the Dalian Star Future Fund, which focuses on investing in early-stage medical technology companies [20] - A recent agreement was made for a transfer of partnership shares within the fund, maintaining the company's shareholding percentage at 51% [21][23] - The new partner, Dalian Jinyun, has no prior relationship with the company and does not hold any shares in it [24]